The new indications for biologicals in type 2 diseases: perspectives.

Abstract

PURPOSE OF REVIEW:

To provide a literature review of what is on the market and under study for some diseases treated with drugs targeting type 2 (T2) inflammation.

RECENT FINDINGS:

Literature data have shown that drugs targeting type 2 inflammation are effective in asthma and nasal polyposis, conditions for which they are on the market, and have promising expectations in the case of eosinophilic esophagitis, especially using anti-IL-5/IL-5 receptor and IL-4 receptor antibodies, while concerning eosinophilic granulomatosis with polyangitis (EGPA), mepolizumab (MEP) was approved by FDA and EMA as a drug for the treatment of this condition because of the promising results obtained in trials and in real life.

SUMMARY:

The use of these drugs is certainly an important achievement in the treatment of complex diseases such as those mentioned above, which are too often orphaned from innovative treatments and limited to the use of immunosuppressants and systemic corticosteroid for their control.

• Authors: Diego Bagnasco, Rikki Frank Canevari, Giovanni Passalacqua, Marco Caminati
• Journal: Current opinion in allergy and clinical immunology (Curr Opin Allergy Clin Immunol) Vol. 22 Issue 6 Pg. 402-408 (12 01 2022) ISSN: 1473-6322 [Electronic] United States
• PMID: 36165457 (Publication Type: Review, Journal Article)
• Copyright: Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Interleukin-5
• Biological Products

Topics

• Humans
• Interleukin-5
• Biological Products (therapeutic use)
• Asthma
• Eosinophilic Esophagitis (drug therapy)
• Inflammation
• Granulomatosis with Polyangiitis (drug therapy)